Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 in Slowly Progressing AML
NCT00003148Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 1997
- Primary completion
- Apr 2001
- Modality
- Cytokines & Interferons
- Countries
- 6
01
Overview
A Phase 2 trial of aldesleukin in acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Started Oct 1997; status: completed.
02
Drugs
aldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003148.